ArticleTherapeutic drug monitoring2017
An Atmospheric Pressure Chemical Ionization MS/MS Assay Using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine.
Article in Therapeutic drug monitoring, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 74 citations in OpenAlex.
- Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2024Trial
- Acute Effects of Ad Libitum Use of Commercially Available Cannabis Products on the Subjective Experience of Aerobic Exercise: A Crossover Study.Sports medicine (Auckland, N.Z.) · 2024Trial
- Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.Drug and alcohol dependence · 2024Trial
- Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and ΔEuropean journal of clinical pharmacology · 2022Trial
- Effects of cannabidiol in cannabis flower: Implications for harm reduction.Addiction biology · 2022Trial
- Inhaling high THC cannabis acutely increases inflammation but not insulin sensitivity: a quasi-randomized trial.Scientific reports · 2026Article
- Analysis of seven selected cannabinoids in human plasma highlighting matrix and solution stability assessments.Journal of analytical toxicology · 2026Article
- Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for a Prospective Cohort Study.JMIR research protocols · 2026Article
- Cannabis, Pain, and Complications: A Prospective Analysis of Cannabis Use, Opiate Consumption, and Postoperative Outcomes following Cancer-Related Abdominal Surgery.Annals of surgical oncology · 2026Observational
- Enhancing data compatibility in an evolving landscape: Medical cannabis and polysubstance use protocols in the PhenX Toolkit.Drug and alcohol dependence · 2026Article
- Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort.Journal of cannabis research · 2025Article
- The Cannabis Use Disorder Identification Test - Consumption (CUDIT-C) as a targeted tool for cannabis use screening.Addictive behaviors · 2025Article
- Cannabinoid Distribution and Clearance in Feeding Spent Hemp Biomass to Dairy Cows and the Potential Exposure to ΔJournal of agricultural and food chemistry · 2025Article
- Mode matters: exploring how modes of cannabis administration affect THC plasma concentrations and subjective effects.Journal of cannabis research · 2025Article
- Article
- Inflammatory state moderates response to cannabis on negative affect and sleep quality in individuals with anxiety.Frontiers in behavioral neuroscience · 2025Article
- The impact of cannabis use proximal to sleep and cannabinoid metabolites on sleep architecture.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- Priming lymphocyte responsiveness and differential T cell signaling in pediatric IBD patients withbioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAlthough, especially in the United States, there has been a recent surge of legalized cannabis for either recreational or medicinal purposes, surprisingly little is known about clinical dose-response relationships, pharmacodynamic and toxicodynamic effects of cannabinoids such as Δ9-tetrahydrocannabinol (THC). Even less is known about other active cannabinoids.
methodsTo address this knowledge gap, an online extraction, high-performance liquid chromatography coupled with tandem mass spectrometry method for simultaneous quantification of 11 cannabinoids and metabolites including THC, 11-hydroxy-Δ9-tetrahydrocannabinol, 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid, 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-C-gluc), cannabinol, cannabidiol, cannabigerol, cannabidivarin, Δ9-tetrahydrocannabivarin (THCV), and 11-nor-9-carboxy-Δ9-tetrahydrocannabivarin (THCV-COOH) was developed and validated in human urine and plasma.
resultsIn contrast to atmospheric pressure chemical ionization, electrospray ionization was associated with extensive ion suppression in plasma and urine samples. Thus, the atmospheric pressure chemical ionization assay was validated showing a lower limit of quantification ranging from 0.39 to 3.91 ng/mL depending on study compound and matrix. The upper limit of quantification was 400 ng/mL except for THC-C-gluc with an upper limit of quantification of 2000 ng/mL. The linearity was r > 0.99 for all analyzed calibration curves. Acceptance criteria for intrabatch and interbatch accuracy (85%-115%) and imprecision (<15%) were met for all compounds. In plasma, the only exceptions were THCV (75.3%-121.2% interbatch accuracy) and cannabidivarin (interbatch imprecision, 15.7%-17.2%). In urine, THCV did not meet predefined acceptance criteria for intrabatch accuracy.
conclusionsThis assay allows for monitoring not only THC and its major metabolites but also major cannabinoids that are of interest for marijuana research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.